Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease

Clinical and Experimental Hypertension

Volumn 33, Issue 6, 2011, Pages 366-372

  Ishimitsu, Toshihiko ^a   Ohno, Eri ^a   Nakano, Nobuyuki ^a   Furukata, Satoshi ^a   Akashiba, Akira ^a   Minami, Junichi ^a   Numabe, Atsushi ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Calcium channel blocker; Chronic kidney disease; Controlled release nifedipine; Fixed dose combination

Indexed keywords

ALBUMIN; HYDROCHLOROTHIAZIDE; LOSARTAN; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; URIC ACID;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID METABOLISM; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VISCOELASTICITY;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; NIFEDIPINE; TREATMENT OUTCOME;

EID: 80053230486     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.503299     Document Type: Article

References (29)

1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
2. Ishimitsu T. Points at issue in the Japanese Society of Hypertension's Guidelines for the Management of Hypertension (JSH2009). Jpn J Nephrol 2009;51:456-460.
3. Ando Y, Ito S, Uemura O, et al. CKD Clinical Practice Guidebook. The essence of treatment for CKD patients. Clin Exp Nephrol 2009;13:191-248.
4. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: The NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23: 445-453. (Pubitemid 40279649)
5. Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: The adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res 2006;29:789-796. (Pubitemid 44842814)
6. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int 2008;73:1303-1309. (Pubitemid 351693145)
7. Buchner N, Banas B, Kramer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008;359:426.
8. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
9. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressureindependent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006;13: 101-107.
10. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res 2008;31:1347-1355.
11. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.
12. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
13. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
14. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372. (Pubitemid 30487492)
15. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial. Arch Intern Med 2004;164:2459-2464. (Pubitemid 39628073)
16. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990;335: 1109-1113.
17. Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). Am J Cardiol 2002;89: 1414-1416. (Pubitemid 34607784)
18. Shinoda E, Yui Y, Kodama K, et al. Quantitative coronary angiogram analysis: Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005;45:1153-1158. (Pubitemid 40770320)
19. MRC trial of treatment of mild hypertension: Principal results. Medical Research Council Working Party. Br Med J 1985;291:97-104.
20. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300:975-978. (Pubitemid 20144223)
21. Suzuki K, Ishizuka N, Miyashita H, Shirai K. CAVI; Toward the standarization of non-invasive blood pressure independent arterial wall stiffness parameter -epidemiological study. Electronics Clinical Science 2008;76:35-45.
22. Kita T, Tokashiki M, Kitamura k. Long-term therapy with nifedipine-CR improves arterio-sclerosis retated markers in patients with untreated essential hypertension. The Open Hypertension Journal 2008;1:1-6.
23. Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: Clinical implications. Am J Cardiovasc Drugs 2001;1:387-397.
24. Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793-797. (Pubitemid 35314777)
25. Yokoyama S, Mori N, Takayama S, Hosino T, Kaburagi T. Renal effects of nifedipine, a calcium antagonist, administered as anti-hypertensive drug. Jpn J Nephrol 1985; 27:1451-1457 (Pubitemid 16234796)
26. Pevahouse JB, Markandu ND, Cappuccio FP, Buckley MG, Sagnella GA, MacGregor GA. Long term reduction in sodium balance: Possible additional mechanism whereby nifedipine lowers blood pressure. Br Med J 1990; 301:580-584. (Pubitemid 20346535)
27. Hamada T, Hisatome I, Sugihara S. Effect of nifedipine coatcore for the prevention of myofibril hyperuricemia in essential hypertensive patient. Prog Med 2004;24: 1285-1288.
28. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009;32:962-968.
29. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-1685. (Pubitemid 28306794)